/
/
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
This content is Free Access.
Chapters
- 00:05Title
- 01:29Preparation of Plasmid DNA Encapsulated EGRF-targeted Gelatin Nanoparticles
- 05:28Determination of Transfection Efficiency by Fluorescence Microscopy
- 07:15Quantitative Determination of Therapeutic Efficiency with Plasmid-encapsulated Nanoparticles
- 08:08Conclusion
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
Tags
Therapeutic Gene DeliveryTransfectionPancreatic Cancer CellsEpidermal Growth Factor Receptor-targeted Gelatin NanoparticlesPancreatic CancerGene TherapyDelivery SystemSustained Transgene ExpressionGelatinDNA EncapsulationPlasmid Supercoiled StructureTransfection EfficiencyThiolation Of GelatinSulfhydryl GroupsDisulfide BondGlutathionePoly(ethylene Glycol)PEG-modified GENSSystemic CirculationTumor MassNeovasculature
